See more : Enel SpA (ENLAY) Income Statement Analysis – Financial Results
Complete financial analysis of SillaJen, Inc. (215600.KQ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of SillaJen, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Orion Office REIT Inc. (ONL) Income Statement Analysis – Financial Results
- TVC Telecom Incorporated (TVCE) Income Statement Analysis – Financial Results
- The Kiley Group, Inc. (KGRI) Income Statement Analysis – Financial Results
- Yamano Holdings Corporation (7571.T) Income Statement Analysis – Financial Results
- Hindustan Zinc Limited (HINDZINC.NS) Income Statement Analysis – Financial Results
SillaJen, Inc. (215600.KQ)
About SillaJen, Inc.
SillaJen, Inc. engages in the development and commercialization of oncolytic immunotherapy products. The company's lead product is Pexa-Vec, which is in Phase II clinical trial for the treatment of advanced liver cancer. It also develops JX-970 for the treatment of tumor tissues; and JX-900 is a series of modified vaccinia vaccine. The company was founded in 2006 and is headquartered in Seoul, South Korea.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.94B | 5.01B | 254.36M | 1.67B | 9.07B | 7.71B | 6.86B | 5.29B | 1.81B | 2.09B |
| Cost of Revenue | 2.48B | 23.78B | 17.54B | 19.40B | 61.37B | 60.10B | 52.08B | 47.76B | 22.73B | 0.00 |
| Gross Profit | 1.46B | -18.77B | -17.29B | -17.73B | -52.30B | -52.39B | -45.21B | -42.47B | -20.92B | 2.09B |
| Gross Profit Ratio | 36.98% | -374.33% | -6,797.34% | -1,061.85% | -576.75% | -679.28% | -658.62% | -802.51% | -1,156.05% | 100.00% |
| Research & Development | 0.00 | 9.41B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 2.50B | 2.26B | 1.65B | 17.29B | 28.13B | 28.01B | 21.66B | 17.11B | 14.33B | 0.00 |
| Selling & Marketing | 10.61B | 13.79B | 9.12B | 7.74B | 36.09B | 35.45B | 32.10B | 31.32B | 7.89B | 0.00 |
| SG&A | 13.11B | -3.73B | 3.09B | 16.93B | 6.19B | 6.89B | 5.40B | 4.35B | 2.85B | 14.95B |
| Other Expenses | 0.00 | 795.61M | 517.85M | -129.99M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 21.78B | 5.68B | 3.09B | 16.93B | 6.19B | 6.89B | 5.40B | 4.35B | 2.85B | 3.99B |
| Cost & Expenses | 25.41B | 29.46B | 20.63B | 36.33B | 67.56B | 66.99B | 57.48B | 52.12B | 25.58B | 3.99B |
| Interest Income | 2.69B | 2.15B | 407.97M | 160.93M | 499.76M | 120.82M | 3.21B | 5.03B | 7.38B | 8.56B |
| Interest Expense | 1.68B | 2.08B | 2.81B | 1.68B | 5.45B | 242.43M | 3.61B | 5.11B | 7.87B | 9.77B |
| Depreciation & Amortization | 1.15B | 1.20B | 1.14B | 1.73B | 3.34B | 3.54B | 3.73B | 3.68B | 3.37B | 2.32B |
| EBITDA | -17.35B | -20.62B | -18.18B | -44.42B | -104.40B | -51.38B | -48.85B | -62.45B | -42.81B | -12.86B |
| EBITDA Ratio | -440.47% | -463.73% | -7,563.48% | -1,972.40% | -608.13% | -722.77% | -683.07% | -815.20% | -1,127.38% | -616.70% |
| Operating Income | -21.35B | -24.45B | -20.38B | -34.66B | -58.49B | -59.28B | -50.62B | -46.82B | -23.77B | -15.18B |
| Operating Income Ratio | -541.83% | -487.63% | -8,011.50% | -2,075.86% | -645.00% | -768.66% | -737.35% | -884.76% | -1,313.62% | -727.77% |
| Total Other Income/Expenses | 1.16B | 545.20M | -2.89B | -13.61B | -54.70B | 307.33M | -5.56B | -24.41B | -30.28B | 12.70B |
| Income Before Tax | -20.18B | -23.90B | -22.12B | -47.82B | -113.20B | -55.43B | -56.18B | -71.24B | -54.05B | -2.48B |
| Income Before Tax Ratio | -512.27% | -476.75% | -8,698.00% | -2,864.25% | -1,248.23% | -718.78% | -818.39% | -1,346.09% | -2,986.59% | -118.79% |
| Income Tax Expense | 188.00M | 691.67M | -6.82B | 3.00 | 3.58M | 803.65M | 839.73M | 2.80B | 1.80B | 0.00 |
| Net Income | -20.37B | -24.59B | -15.31B | -47.82B | -113.20B | -56.24B | -57.02B | -74.04B | -55.85B | -2.48B |
| Net Income Ratio | -517.04% | -490.55% | -6,017.12% | -2,864.25% | -1,248.27% | -729.20% | -830.62% | -1,398.97% | -3,086.09% | -118.79% |
| EPS | -179.98 | -221.44 | -167.79 | -618.29 | -1.48K | -737.49 | -795.30 | -1.45K | -906.59 | -116.00 |
| EPS Diluted | -179.98 | -221.44 | -167.79 | -618.29 | -1.48K | -737.49 | -795.30 | -1.45K | -906.59 | -116.00 |
| Weighted Avg Shares Out | 113.18M | 111.06M | 91.22M | 77.35M | 76.42M | 76.25M | 71.70M | 50.98M | 61.61M | 21.36M |
| Weighted Avg Shares Out (Dil) | 113.18M | 111.06M | 91.22M | 77.35M | 76.42M | 76.25M | 71.70M | 50.98M | 61.61M | 21.36M |
Source: https://incomestatements.info
Category: Stock Reports